Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T17:52:51.695Z.
Calculation as of: 2026-10-06T17:52:51.695Z.
Quote observation: 2026-10-06T17:50:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 310997c20848bd5012eb98bb82f11fa46ca59880ef1b58a452bebfeaa3e5ded1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Phathom Pharmaceuticals, Inc.
Market Cap
$530.71M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$534.45M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$535.09M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$535.43M
Free Cash Flow Yield
3.27%
TTM Avg
3.62%
3Y Avg
3.23%
5Y Avg
3.23%
Market Cap
$535.61M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$536.98M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$520.08M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | $530.71M | N/A | N/A | N/A | N/A |
| Monopar Therapeutics Inc. (MNPR)vs › | $534.45M | N/A | N/A | N/A | N/A |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $535.09M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $535.43M | 3.27% | 3.62% | 3.23% | 3.23% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $535.61M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $536.32M | N/A | N/A | N/A | N/A |
| Nuvectis Pharma, Inc. (NVCT)vs › | $536.98M | N/A | N/A | N/A | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $540.91M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $520.08M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $517.30M | N/A | 536.25% | 536.25% | 536.25% |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
